Brief: SynAct Pharma Q2 Net Income at SEK -43.511 Million
04/08/2023 06:34
Aug 4 (Reuters) - SynAct Pharma Q2 adjusted EPS SEK -1.37. * Q2 cash flow from operating activities SEK -34.657 million * Q2 sales SEK 0 * Q2 net income SEK -43.511 million * Q2 operating expenses SEK 43.495 million
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026